Teva announces its launch of the first generic perforomist®, formoterol fumarate inhalation solution, 20 mcg/2 ml, used to treat chronic obstructive pulmonary disease (copd), in the united states

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced its u.s. launch of the first generic version of twice daily perforomist®, formoterol fumarate inhalation solution, 20 mcg/2 ml, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. “teva is pleased to provide patients with first-to-mar
TEVA Ratings Summary
TEVA Quant Ranking